Our Blog



chem-1200x675.jpg
02/Jul/2021

Ciprofloxacin

Overview

Ciprofloxacin is a fluoroquinolone antimicrobial agent with a broad spectrum of activity against both gram-negative and gram-positive bacteria. It relatively non-toxic and well tolerated broad spectrum agent. Excellent bioavailability permits its use for treatment of variety of serious bacterial infections. Require constant drug level in body for therapeutic effect. This is achieved by taking the medication at regular interval of time throughout the day and night as prescribed. For Ciprofloxacin (HCl) it important to take the drug for the full time period as prescribed. If you discontinue the therapy it may result in ineffective treatment.
Ciprofloxacin (HCl) is the monohydrated hydrochloride salt of ciprofloxacin. Ciprofloxacin (HCl) is effective against many gram positive and gram negative bacteria, including some strains resistant to penicillins, cyclosporins and aminoglycosides.

Primary Characteristics

Ciprofloxacin (HCl) is the derivative of Ciprofloxacin. It is of Semi Synthetic origin and belongs to Quinoline Carboxylic Acid. It belongs to DNA Gyrase inhibitor pharmacological group on the basis of mechanism of action and also classified in Antibiotics pharmacological group. The Molecular Weight of Ciprofloxacin is 346.00. Its pKa is 6-8.8.

Indications

Ciprofloxacin primarily indicated in conditions like Acromegaly (short-term treatment before pituitary surgery), Chronic prostatitis, GI infections, Gonorrhoea, Iron-deficiency anaemia prophylaxis or for mild iron deficiency, Iron-deficiency anaemia with chronic renal failure, Most other infections, Muscle relaxation (long duration) for surgery and intubation, , Osteomyelitis, Pseudomonal lower+RTI in cystic fibrosis, Respiratory tract infections, Sexually transmitted disease, Sexually transmitted infections, Skin infections, Skin structure infections, Status epilepticus (unlicensed use), Surgical prophylaxis, Urinary tract infection.

 

Pharmacokinetics

Oral absorption of Ciprofloxacin is found to be 67% ±17. Volume of distribution is found to be 177-217 litre and plasma protien binding 30%. and metabolism reported 5% via liver. Renal Excretion accounts for 70% unchanged, 10% metabolites of IV dose and plasma half life is 3-4 hr.

 

 Mechanism of action

Ciprofloxacin acts on bacterial topoisomerase II (DNA gyrase) and topoisomerase IV. Ciprofloxacin’s targeting of the alpha subunits of DNA gyrase prevents it from supercoiling the bacterial DNA which prevents DNA replication.

Metabolism

Ciprofloxacin is primarily metabolized by CYP1A2. The primary metabolites oxociprofloxacin and sulociprofloxacin make up 3-8% of the total dose each. Converted to the minor metabolites desethylene ciprofloxacin and formylciprofloxacin. These 4 metabolites account for 15% of a total oral dose.

There a lack of available data on the enzymes and types of reactions involved in forming these metabolites.

Contraindications

Ciprofloxacin is contraindicated in conditions like Epilepsy, and Hypersensitivity.

Side Effects

The severe or irreversible adverse effects, which give rise to further complications include Hearing loss, Seizures and Pseudomembranous colitis.

Produces potentially life-threatening effects which include Anaphylactoid reactions, Stevens Johnson syndrome, Acute Renal Failure, Epidermal necrolysis, Fluminant hepatic failure. which are responsible for the discontinuation of Ciprofloxacin therapy.

The symptomatic adverse reactions produced by Ciprofloxacin are more or less tolerable and if they become severe, they can treated symptomatically, these include Dizziness, Headache, Nausea, Vomiting, Diarrhoea, Tachycardia, Nervousness, Tremors, Rashes, Urticaria, Pruritus, Photosensitivity, Elevation of liver enzymes, Thrombocytopenia, Eosinophilia, Increased intracranial pressure, nervousness, joint symptoms, agranulocytosis.

Warning / Precautions

Ciprofloxacin used with caution in patients with known or suspected central nervous system (CNS) disorders, renal impairment or hepatic disease, with a history of GI disease especially colitis or who dehydration. Do not exceed the recommended dose. Take appropriate measures if secondary infections occur.

 

Storage Conditions

Eye Solution/ Eye ointment

Store at room temperature, Below 30°C or in refrigerator. Do not Freeze. Protect from Sunlight.

Injection (reconstituted solutions)

Store at room temperature, Below 25°C or in refrigerator. Do not Freeze. Protect from Sunlight. Use within 2 weeks if kept at room temperature.

Store .

 

Interference in Pathology

Elevations of SGPT and SGOT

Serum creatinine raised

Elevation in ALT or AST

blood urea raised.

 

Vision Pharmaceuticals (PVT) Limited

Vision Pharmaceuticals are one of the best pharmaceuticals companies of the world. Different types of pharma products & drug pellets we manufacture speak volumes of the high quality, efficacy & durability. If you have any query or want to know about any product, contact us on following numbers;

+92 (051) 449 3587, +92 (51) 449 3589, +92 (321) 517 1779


f-1200x675.jpg
01/Jul/2021

cyclobenzaprine hydrochloride

Overview

Cyclobenzaprine hydrochloride is a tricyclic amine salt with the empirical formula C20H21N•HCl. Cyclobenzaprine is a central nervous system (CNS) muscle relaxant intended for short-term use in the treatment of pain, tenderness, and limitation of motion caused by muscle spasms. It is thought to act within the CNS at the brain stem rather than spinal cord levels, although action at the spinal cord level may contribute to some of its skeletal muscle relaxant action.

Primary Characteristics

. It belongs to Muscle Relaxants pharmacological group on the basis of mechanism of action. The Molecular Weight of cyclobenzaprine hydrochloride is 311.90. Its pKa is 8.47.

Indication

Cyclobenzaprine is indicated as a short-term (2-3 weeks) adjunct therapy, along with rest and physical therapy, for relief of muscle spasm associated with acute, painful musculoskeletal conditions. It not been found effective in the treatment of spasticity originating from cerebral or spinal cord disease, or spasticity in children with cerebral palsy. Cyclobenzaprine is also occasionally used off-label for reducing pain and sleep disturbances in patients with fibromyalgia.

Pharmacokinetics

Oral absorption of cyclobenzaprine hydrochloride is found to be 44% ±11. Plasma protein binding is high. and metabolism is reported P-450 3A4, 1A2, and, to a lesser extent, 2D6. Renal Excretion accounts for as glucuronides and plasma half life is 18 Hours.

 

Contraindications

Cyclobenzaprine hydrochloride is contraindicated in conditions like Hyperthyroidism, Congestive heart failure, Hypersensitivity to any component of product.

Pharmacodynamics

Cyclobenzaprine is a skeletal muscle relaxant that works on areas of the brainstem to reduce skeletal muscle spasm, though its exact pharmacodynamic behavior is currently unclear. Despite its long half-life, it is relatively short-acting with a typical duration of action of 4-6 hours. Cyclobenzaprine has been reported to contribute to the development of serotonin syndrome when used in combination with other serotonergic medications. Symptoms of serotonin syndrome may include autonomic instability, changes to mental status, neuromuscular abnormalities, or gastrointestinal symptoms. treatment with cyclobenzaprine should be discontinued immediately if any of these reactions occur during therapy.

Mechanism of Action

The exact mechanism of action of cyclobenzaprine has not been fully elucidated in humans, and much of the information available regarding its mechanism has been ascertained from early animal studies. There is some evidence that cyclobenzaprine exerts its effects at the supraspinal level, specifically within the locus coeruleus of the brainstem, with little-to-no action at neuromuscular junctions or directly on skeletal musculature. Action on the brainstem is thought to result in diminished activity of efferent alpha and gamma motor neurons, likely mediated by inhibition of coeruleus-spinal or reticulospinal pathways, and ultimately depressed spinal cord interneuron activity.

More recently it has been suggested that inhibition of descending serotonergic pathways in the spinal cord via action on 5-HT2 receptors may contribute to cyclobenzaprine’s observed effects.

Metabolism

Cyclobenzaprine is extensively metabolized in the liver via both oxidative and conjugative pathways. Oxidative metabolism, mainly N-demethylation, is catalyzed primarily by CYP3A4 and CYP1A2 (with CYP2D6 implicated to a lesser extent) and is responsible for the major metabolite dimethyl cyclobenzaprine. Cyclobenzaprine also undergoes N-glucuronidation in the liver catalyzed by UGT1A4 and UGT2B1, and has been shown to undergo enterohepatic circulation

Half-life

The effective half-life of cyclobenzaprine in young healthy subjects is approximately 18 hours. These values are extended in the elderly and those with hepatic insufficiency, with a mean effective half-life of 33.4 hours and 46.2 hours in these groups, respectively

Side Effects

The severe or irreversible adverse effects of cyclobenzaprine hydrochloride, which give rise to further complications include Irregular heart beat.

cyclobenzaprine hydrochloride produces potentially life-threatening effects which include Hypersensitivity reactions. which are responsible for the discontinuation of cyclobenzaprine hydrochloride therapy.

The signs and symptoms that are produced after the acute over dosage of cyclobenzaprine hydrochloride include Nausea, Tachycardia, Hallucinations, Drowsiness, Changes in ECG, Slurred speech, Dizziness, Coma, Severe hypotension, Seizures, Cardiac dysrhythmias, Confusion, Tremor, Vomiting, Ataxia, Agitation, Hypertension.

The symptomatic adverse reactions produced by cyclobenzaprine hydrochloride are more or less tolerable and if they become severe. They can be treated symptomatically, these include Headache, Drowsiness, Fatigue, Nausea, Diarrhea, Constipation, Abdominal pain, Dry mouth, Acid regurgitation.

Warning / Precautions

Use of Cyclobenzaprine Hydrochloride for periods longer than two or three weeks is not recommended. Less frequent dosing should be considered for hepatically impaired or elderly patients. It is contraindicated in acute recovery phase of myocardial infarction, and patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure. Used with caution in elderly patients with reduced doses. It should be used with caution in patients with a history of urinary retention. Angle closure glaucoma, increased intraocular pressure, and in patients taking anticholinergic medication. Used with caution in subjects with mild hepatic impairment starting with a 5 mg dose and titrating slowly upward. In subjects with moderate to severe impairment is not recommended. Safety and effectiveness of cyclobenzaprine hydrochloride in pediatric patients below 15 years of age have not been established.

 

Storage Conditions

Store Between 15°C-30°C.

 

 

Vision Pharmaceuticals (PVT) Limited

Vision Pharmaceuticals are one of the best pharmaceuticals companies of the world. Different types of pharma products & drug pellets we manufacture speak volumes of the high quality, efficacy & durability. If you have any query or want to know about any product, contact us on following numbers;

+92 (051) 449 3587, +92 (51) 449 3589, +92 (321) 517 1779

 


sterile-powder-for-injection-1200x675.jpg
06/Nov/2020

Vision Pharmaceutical’s powders for injections are sterile, pyrogen-free powder substances including our lyophilized material packed in glass container. When sterile water for injection (provided in the packaging) added into this powder. it rapidly form a clear solution that can injected intravenously or intramuscularly.

Parenteral preparations may require the use of excipients such as solvents, substances to enhance solubility, suspending agents, buffering agents, substances to make the preparation isotonic with blood, stabilizers or antimicrobial preservatives. Vision Pharmaceutical ensures that these addition of excipients kept to a minimum. Our R&D department thoroughly investigate and then recommends specific excipients so that they do not adversely affect the stability, bioavailability, safety or efficacy of the active ingredient. It ensured that all the components of the dry powder ampules perfectly compatible with each other.

Manufacture:

Vision Pharmaceutical strives to make sure that our manufacturing process meet the standard of cGMP. The following main general guidelines followed at every step of production to meet the requirements.

The quality and grade of raw material, manufacturing machinery, maintenance of the equipment and the method of powder production. maintained at highest standard to ensure the stability of the active substance and of the final product and that the final product sterile and free of pyrogens and particulate matter.

If any antimicrobial agent added, the quantity kept minimum and according to guidelines provided by regulatory authority. Sterilisation performed prior to production and maintained throughout the procedure. For glass container sterilisation autoclave the preferred method because it ensures rapid and complete sterilisation.

Vision Pharmaceutical extra cautious in filling of oxidation sensitive formulas and filling of such powder done in the atmosphere of suitable sterile inert gas, such as nitrogen, whereby the air in the container replaced by this gas.

Suitable and controlled particle size in maintained, dependent upon the intended use of the dry powder formulation.

Vision Pharmaceutical monitors manufacturing process by validation and carrying out appropriate in-process controls. These chalked out in a way to guarantee effectiveness of each stage of production. Monitoring of environmental conditions (especially with respect to particulate and microbial contamination), bacterial endotoxins, pH and clarity of solution. Freedom from particulate matter and integrity of the container-closure system (absence of leakage, etc.) utmost importance in this regard. We ensure that production procedure of powders for injections must include uniformity of mass, moisture content and the ease of reconstitution.

Our quality control department validate every production phase and inspect final product for particulate matter, discoloration. Precipitation of solid matter and other sign of chemical or physical instability. Vision Pharmaceutical guarantees that all our parenteral preparations comply with Test for sterility. Test for bacterial endotoxins, or, where applicable with Test for pyrogens. In single active ingredient formula it ensured that the Sterile Powder for Injection must  uniform mass and particle size.


pellet-formation-1200x675.jpg
06/Nov/2020

Drug Pellet formation may appear as semicircular granules to an unaided eye. But is it the same plain, old, bitter tastings medicinal stuff, nay! It indeed a marvelous of modern pharmaceutical research. We at Vision Pharmaceutical put literally our heart and soul with critical Thinking brains and expert hands into making drug palletization a reality and its wider availablity to local as well as international consumers.

Vision Pharmaceutical with its focused and result oriented R&D makes the formation of nearly spherical particles into final, pellitized product possible undergoing the process of fine particulating ,tumble drying, addition of binders and additives in various pellitization equipment.

Our unique pellitization techniques make us not only on par with any standardized international pellet manufacturers but give us un upper hand in economically competitive market as well. Drug Pellets manufacturing an art in itself and undergoes stages of production under uber scientific principles. What factors work deep down in these processing and how complicated it  ,let us have a look.

At first moist content of dried particles is reduced to form an effective air water interface. Make a granulation of particles possible with the help of both physical and applied forces. Physical forces impart tensile strength and liquid bridging among particles, changing capillary and surface tension of granules.

At Vision Pharmaceutical purpose built fully automated manufacturing unit makes tumbling motion of the particles possible and applied forces.   That arise as a result bring individual wetted particles close to each other and uniform distribution of active ingredients. This mechanism makes it possible to initiate pellitization process and subsequent growth of individual pellets under the following factors.

  1. Nucleation

Nucleation the Formation of nuclei and the process of particles formation from the continuos phase via interaction within the physical environment. In this stage liquid bridges created making formation of three dimensional water-air-liquid bonding possible, this give particles specific physical appearance and properties. Vision Pharmaceuticals makes sure that particles size must kept smaller for better bonding strength.

  1. Coalescence:

The second stage is coalescence, its a transition stage. This region affected by growth factors of coalescence and drug layering. Very important indeed so it needs to be closely supervised and Our R&D strives to make the process up to date. Coalescence brings discreet changes to size and no of particles but not to their mass.

  1. Layering

Layering is a third and final factor in manufacturing process of pellet formation. It is a continuous phase where both size and properties of particulate matter changes with drug layering. Vision Pharmaceutical advanced, fully automated production facility. Makes its possible to layer single or multiple active drugs on a single granule. Masking of bitter tastings drugs with addition of layers of Tasteless additives also ensured in this process.

All these Physical and Chemical processes work simultaneously in delicate ways to make scientifically quantified, tasteless, single/multi ingredient active drug pellets a reality and Vision as a pioneer in the science of pellitization.


pellitization-techniques-1200x675.jpg
06/Nov/2020

Vision Pharmaceutical has one of a kind, state of art production machinery. That unique in its own way and utilise every modern pellitization Techniques, a quality unmatched in local market as well as neighbouring India. A Vision Pharmaceutical fully automated plant, R&D and Quality control department work in synchronisation to produce products with unmatched quality, economy, efficacy and Heartfelt satisfaction from our end consumers.

Vision Pharmaceutical utilises every modern standardised technique and pharmaceutical manufacturing procedures to produce drug pellets of unmatched quality.

We herby Discuss Vision Pharma’s pellitization Techniques in detail.

Extrusion Spheronization:

This technique widely used in modern pellitization worldwide. Vision Pharmaceutical utilises it as a major pellitization procedure in its operations. Our unique extrusions Spheronization takes place in three steps.

. Feed preparation

. Pellets production

. Pellets curing

Feed preparation, the first step and it initiated by mixing of drug-excipients with desired additives such as solution of binding agents. Then the second and most important step follows, and the process of agglomeration, where desired size of pellets are formed in pellitizater. The final step curing of wet pellets by thermal drying. Vision Pharmaceutical also utilises technique of simple stockpiling for some drug pellets.

The pellitization begins with the dispensing of powder feed material with binding solutions to the granulator to form a plasticized wet mass. This mass allowed to the screening chamber of extruder. Here pressure blades provide enough Compression to wet mass against the exterior of the screen. The extruder material discharged into discharge unit through scrapper blade and then finally into Spheronizer. Pellitizer disk  rolls the extruded with high speed in the direction of the roller and a rolling movement of helical like structure takes place. This makes the extrudes smooth in short amount of time. Due to intense rolling action and finally uniformed and spherical pellets discharged at the discharge unit.

More about Pellitization Technique

Pellitization Technique needs careful evaluation and continuous monitoring.  Vision Pharmaceutical’s production and quality control departments keep a keen eye. Monitors and document the whole process according to strict guidelines at every step of production. We ensure that every step thoroughly followed and not even a slight mistake is tolerated. We at Vision ensure that.

. In order to produce pellets of uniform size and shape the whole procedure of spheronization properly optimized.

. Extrudate should be in proper wet condition before entering spheronizer. So that it can be spheronized smoothly and no further breakdown occur.

. Different types of extruders are used for different formulations in order to achieve uniform pellitization.

. Amount of binders strictly controlled to avoid hardness and irregular shapes of pellets.

. Formation of big lumps of pellets  avoided at every cost.

. This type of pellitization process  more labor intensive but result in very ideal uniform shaped also spherical pellets.


drug-pellets-properties-1200x675.jpg
06/Nov/2020

Drug Pellets must have specific Pharmaceutical Properties to be considered as better alternative to conventional dosage forms. Vision Pharmaceutical ensures the highest possible standard of these requisites, both qualitatively and quantitatively and our formulated pellets best example of ,what benefits do this scientific novice and far better dosage form carries. Vision Pharmaceutical ensures that every standardised procedure and SOPs are thoroughly followed to impart unique qualities to our Drug Pellets.

At every phase of Pellets production Vision Pharmaceutical ensures that our end products comply all international standards and posses quality that second to none. Our highest qualified workforce and Fully Automated Plant ensures that no stone left unturned to achieve the goal of Ideal pellitization equipped with best Pharmaceutical properties.

In contrast to Semi Automated Production plant ,our Fully Automated Production Unit omits any chance or possibility of human error. Vision Pharmaceutical takes pride in drug pellitization, where every individual pellet carry unmatched Pharmaceutical qualities.

Size:

Pellets as drug delivery carries must have uniform size, almost spherical shape and free flowing properties. Vision Pharmaceutical drug Pellets have unifrom size and flow properties that guarantee best subsequent encapsulation and compression.

Shape and Tensile strength:

We at Vision Pharmaceutical make sure that our formulated pellets have a specific comparatively better tensile strength. The single most important Pharmaceutical property of our pellets that provide our end product with targeted drug delivery module.

Our oral contral release medication posses  qualities of dispersion all along the Gastrointestinal tract and exhibits prolong GI transit time. The tensile strength of our pellets impart it with sufficient mechanical strength to withstand abrasion during handling and further processing.

Shape and size play important role in dissolution and disintegration of drug pellets. Shape and size determing factors in devising dose strenght as pellets’ particles may form cluster and may remain there for long time within stomach even when food expelled out of stomach long before.

Smaller pellets of less then 2.4 mm diameter not affected by digestive functioning and closing down of pyloric sphincter. For multi unit drug pellets the ideal diameter 1.5 mm. Vision Pharmaceutical ensures that particle size standards strictly maintend.

Vision Pharmaceutical pellets production unit follows strict guidelines in maintaining the Ideal tensile strength of pellet granules. Our Pellets posses strength enough to withstand handling, transportation, storage, and further processing. We at Vision focus on strength of both wet and dry pellets.

Vision Pharmaceutical use a combination of additives and production techniques to ensure that our pellets posses ideal qualities. Quantity and nature of Adhesive , moisture content, salts and binders used in order to increase the strength of pellets.


lyophilization-1200x675.jpg
06/Nov/2020

Pellets are prepared by utilisation of freeze drying method in this technique. Vision Pharmaceuticals employs industry leading Lyophilisation techniques and produces highest quality sustained release, taste masked pellets that otherwise impossible to manufacture due to water sensitivity. Liquid nitrogen (-196 °C) is used as a medium, that causes freezing of droplets of liquid formulations into solid spherical particles which, then Lyophilised to produce pellets.

In this technique material freezes Immediately and uniformly due to rapid heat transfer from material’s droplets to liquid nitrogen. The total amount of liquid nitrogen required dependent upon quantity of solution. The equipment consists of a nitrogen container and a conveyor which with its variable speed maintains the required residence time for freezing the Pellets. Frozen pellets stored in a storage container (Temperature -60°C ) before drying. In this process droplet formation a critical step influenced by many variables like nature, viscosity, surface tension, solid content of the solution and equipment design.

Hot Melt Extrusion:

HME a robust and novel technique used in Pharmaceutical industry to produce various drug delivery system. This technique utilised by  very few Pharmaceutical industries throughout South Asia, Vision Pharmaceutical proud of its engineering unit to utilise such a novel and advanced manufacturing system.

This method involves compaction and blend of powder into uniform shaped pellets. Melted polymers, binders, excipients and active drugs forced through a die under control temperature, pressures, screw speed etc to form uniform shaped pellets.

Whole process carried out in following major steps.

Feeding of extruder through hopper.

Mixing, grinding, kneading.

Flow through the die under controlled conditions.

Extrusion and further processing.

Vision Pharmaceutical uses this technique for the variety of benefits including but not limited to.,

. Pellitization of drugs with poor bioavailability.

. For preparation of taste masked dosage forms.

. To make a stable dosage form,in case the drug water sensitive.

. Formulation preparation for control release dosage forms.

. For uniform suspension of drug particles with better content uniformity.

Freeze Pellitization:

In this technique, a molten solid carrier into which the drug uniformly dispersed entered as tiny droplets into, inert liquid in which molten solid carrier completely immiscible. This tiny droplets get solidified Into spherical pellets. These tiny droplets can move in either direction depending upon the density of the solid carrier. If the density lower compared to inert liquid than molten solid is introduced from the bottom and droplets will flow from bottom to upward coulmn. But if the density higher than inert liquid then molten solid introduced from the upward coulmn. Melting point of solid carrier used for this process below 100°C so that it can remain solid at room temperature. In order to obtain uniform shaped spherical pellets. Viscosity of the drug medium should be optimum, ideally between 4 and 40 cP at 20 °C.


layering-technique-1200x675.jpg
06/Nov/2020

Another common pellitization technique employed by Vision Pharmaceutical layering technique. This production technique predominantly used for taste masked and control release formulations. This technique of two types, solution layering and powder layering.

In solution layering powder feed material and other components dissolved in solvent. Then this solution or suspension sprayed on the starter core and spread evenly on the surface. Spraying follow by drying phase, in this phase dissolved material get crystallized and solid bridges formed between drug and polymers. Vision Pharmaceutical controls drying method very strictly because drying can affect structural and functional properties of pellets. Various techniques employed by Vision Pharmaceutical’s production unit to increase dissolution properties of pellets.

In powder layering the seeds charged into the pellitizer and on its surface. Then the binder liquid and powder feed material sprayed tangentially. The uniform distribution of powder over the seed surface ensured by rolling movement confirming its spherical shape. It involves uniform deposition of fine drug particles plus excipients on the surface of starting core with the help of binding liquid.

Vision Pharmaceutical never use conventional coating pan ( used by many pellet’s manufacturers even today) due to its limitations, like poor degree of mixing and very inefficient drying. We employ procedures that deliver the powder in such a manner and rate that in equilibrium with the binder liquid application rate throughout the process. We at Vision make sure that no over wetting and dust generation occur as it will reduce the overall quality and yield of products.

Fluidized Bed Processor:

Also called Wurster process, it performs multiple function like coating, drying, granulations and pellitization. Vision Pharmaceutical prepares control release formulations by this technique particularly.

It involves successive deposition of several layers of the coating material. A spray nozzle fitted in the base plate with concurrent air flow and pressurised stream of specific spray pattern. The particles accelerated within the Wruster tube and coating material continuosly sprayed through the spray case. The process continues till appropriate build up on the surface of particles takes place.

Vision Pharmaceutical controls critical parameters in order to avoid powder adherence to side of hopper and if the bed temperature high and there a risk of powder lost to exhaust system. binders consistently used during solution Layering to impart strenght to the pellets.

Our Quality Control parameter ensured that our consumers get best form of sustained released, and taste masked drug pellets.


pellet-evaluation-1200x675.jpg
06/Nov/2020

Vision Pharmaceutical with its unique and state of the art production and quality control techniques takes pride in unparalleled satisfaction of its end consumers through highest standard product portfolio and goal oriented business module. Here Quality control procedures followed at every stage  of production line and final product bring under strict scrutiny.

Vision Pharmaceutical manufacture drug Pellets through its automated plant and evaluate them through various standardized technique. Only pellets that pass through these evaluation measures allowed distribution to market.

Pellet Shape:

We at Vision Pharmaceutical strive to keep our pellets shape uniform and in accordance with international standards. Prime requirements for successful coating spherical and smooth shape of pellets. Both microscopic and non microscopic methods are used to determine Pellets’ shape. Pellet Shape affects its geometric properties, flow and compaction. It possible to determine whether the pellet spherical or asymmetrical. Spherical shaped pellets have minimum surface volume per unit area. The minimum face value is 6 for spherical shape Pellets, if the value exceeds 6 then the pellet is considered asymmetrical.

Size Distribution:

Pellet size equally important factor in addition to shape. Pellet size determined by sieve shaking method and microscopy. Vision Pharmaceutical commonly use sieve shaking method for evaluation of pellet size but microscopic measurements also used whenever need arises.

Surface Morphology:

Surface morphology is another very important parameter in pellets manufacturing. Scanning as well as analysis of cross section of pellets can use to determine surface morphology. Microscopic properties of pellets, structure of pellets’ surface, density and frictional force between the pellets are parameters of utmost importance. Vision Pharmaceutical ensures to impart optimal morphological properties to its manufactured pellets in order to give these ,ideal compression, and disintegration properties.

Tensile strength:

Tensile strength is very important property of drug pellets. In order to evaluate the tensile strength of pellets, Vision Pharmaceutical uses tensile apparatus. Pellets strained under five kg load cell until failure occur. Then tensile strength of that particular drug pellets calculated by using various formula specifically devised by our quality control department.

Crushing strength:

The crushing strength is the measure of load needed to break the pellet. We at Vision Pharmaceutical use material testing machine to measure crushing strenght of various drug Pellets. This process repeated at every step of production line and at end product along with other quality control tests.

Specific Surface Area:

Surface per unit volume called specific surface area. Size and shape of pellets directly affected by this physical property alone. For film coating of pellets, knowledge of specific area is extremely important, but even for uncoated pellets  it has got some importance. As this property directly influence drug release profile, so Vision Pharmaceutical production unit carefully monitor specific surface area of every individual batch of single or multi ingredient drug Pellets evaluation.

Disintegration Time:

Disintegration time very important characteristic for immediate release pellets. It can influence actual drug availability in vitro and peak plasma concentrations at various time intervals. Vision Pharmaceutical uses latest Disintegration Apparatus to measure disintegration time of every batch of drug Pellets.


featured-image-1200x675.jpg
06/Nov/2020

Drug Pellets

Drug Pellets is new form of pharmaceutical drug delivery system manufactured by fine powder excipients. And active drug together to form free flowing spherical or semi spherical granular particles. Vison pharmaceutical provides a vast portfolio of active ingredient formulas in the form of pellets with advance manufacturing facilities.

Benefits as compared to other pharmaceutical dosage forms:

Drug Pellets is relatively newer technique of multi purpose pharmaceutical manufacturing process developed to serve key targets in mind. Vision Pharmaceutical the largest pellets manufacturing pharma in local market serving end customers with plethora of benefits. With our dedicated Research and development team, state of the art manufacturing facilities following strict  cGMP and WHO guidelines, quality assurance at every step of pellets. manufacturing and export oriented corporate module makes us one of the unique pharmaceutical industry that have no parallel in local market. Vision Pharmaceutical has purpose built fully automated manufacturing plant that proves its engineering prowess compared to old age semi automatic Indian Pellets manufacturers.

Vision Pharmaceutical’s goal orientated R&D Team makes drugs pellets manufacturing process not only up to date but takes it forwards to the very cutting edge of technology. Our state of the art quality control facilities ensure strict quality assurance at every step of pellets production. Vision Pharmaceutical bulk manufacturing facilities ensure market competitive price without slightest compromise on quality. Our corporate environment and business module. ensure ease of mind in doing business with Vision for both national/international businesses and end customer.

Vision Pharmaceutical provides following benefits in Drug Pellets manufacturing and end products.

Maximum absorption:

Our pellets ensures maximum absorption and maximum bioavailability.

Comparatively lesser dosage dumping:

Pellets complicated to manufacture but it provides the benefits of lesser dosage dumping. with targeted on site delivery and uniform absorption.

Pulsed,sustained and Delayed release:

Vision Pharmaceutical provides sustained release formulation for the maximum dose efficiency. And sustainable plasma levels by carefully selecting polymers and preparation methods.

Mutiple drug combinations with different release rate:

Vision Pharmaceutical ensures that multiple active ingredients can combined with varied gastrointestinal release rates and without any incompatibly issues.

Masked or tasteless drugs:

Our uniquely manufacturing facilities ensure tasteless or flavoured drug pellitization of bitter tastings formulas for better patients’ compliance

 

Vision Pharmaceuticals (PVT) Limited

Vision Pharmaceuticals are one of the best pharmaceuticals companies of the world. Different types of pharma products & drug pellets we manufacture speak volumes of the high quality, efficacy & durability. If you have any query or want to know about any product, contact us on following numbers;

+92 (051) 449 3587, +92 (51) 449 3589, +92 (321) 517 1779






Get in touch

Contact us now

Vision Pharmaceutical bulk manufacturing facilities ensure market competitive price without slightest compromise on quality

Contact Number

+92 (51) 4493589



Email Address

drabidyaqoob@hotmail.com



Follow us

Our Activity

Follow our social media pages activity for learning more about our services and products


Copyright & Managed by Vision SAP/IT Engineers !

vision pharmapk logo
Top